Impact on patients' health status following early identification of a COPD exacerbation

European Respiratory Journal

Volumn 30, Issue 5, 2007, Pages 907-913

  Bourbeau, J ^a   Ford, G ^c   Zackon, H ^b   Pinsky, N ^d   Lee, J ^e   Ruberto, G ^e  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Abbie J Lane Building   (Canada)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Health related quality of life

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; BUDESONIDE; CANADA; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HEALTH STATUS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 38849168231     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00166606     Document Type: Article

References (27)

1. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585-591.
2. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. Am J Respir Crit Care Med 1997; 156: 1719-1724.
3. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967.
4. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
5. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364.
6. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
7. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395.
8. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
9. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593.
10. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
11. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
12. Anie KA, Jones PW, Hilton SR, Anderson HR. A computer-assisted telephone interview technique for assessment of asthma morbidity and drug use in adult asthma. J Clin Epidemiol 1996; 49: 653-656.
13. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117, 5: Suppl. 2, 398S-401S.
14. Medical Research Council Committee on the Aetiology of Chronic Bronchitis. Standardized questionnaires on respiratory symptoms. BMJ 1960; 2: 1665.
15. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
16. Garcia-Aymerich J, Monso E, Marrades RM, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med 2001; 164: 1002-1007.
17. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
18. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: Suppl. 5, S1-28.
19. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 2003; 10: Suppl. A, 11A-65A.
20. Barr RG, Bourbeau J, Camargo Jr CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-862.
21. Burge P. EUROSCOP, ISOLDE and the Copenhagen city lung study. Thorax 1999; 54: 287-288.
22. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
23. Calverley P, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
24. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091.
25. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
26. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303.
27. Sedeno MF, Nault D, Hamd D, Bourbeau J. A written action plan for early treatment of COPD exacerbations: An important component to the reduction of hospitalizations. Am J Respir Crit Care Med 2006; 3: A603.